UCB (OTCMKTS:UCBJF) Trading Down 4.8% – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s share price fell 4.8% during mid-day trading on Monday . The company traded as low as $233.86 and last traded at $238.40. 412 shares traded hands during trading, a decline of 40% from the average daily volume of 689 shares. The stock had previously closed at $250.52.

Wall Street Analysts Forecast Growth

UCBJF has been the subject of several research analyst reports. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

UCB Stock Down 4.8%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $263.68 and a 200 day moving average price of $285.27.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.